药明生物与ABL Bio针对多个双抗达成**开发与生产战略合作

2018-11-29 美通社 美通社

全球领先的开放式生物制药技术平台公司药眀生物(WuXi Biologics, 2269.HK)与专注于肿瘤免疫和神经退行性疾病抗体新药开发的韩国生物技术公司ABL Bio Corporation(以下简称ABL Bio)今日宣布,双方针对多达八个抗体新药达成独家研发与临床生产战略合作。全球领先的开放式生物制药技术平台公司药眀生物与专注于肿瘤免疫和神经退行性疾病抗体新药开发的韩国生物技术公司ABL

全球领先的开放式生物制药技术平台公司药眀生物(WuXi Biologics, 2269.HK)与专注于肿瘤免疫和神经退行性疾病抗体新药开发的韩国生物技术公司ABL Bio Corporation(以下简称ABL Bio)今日宣布,双方针对多达八个抗体新药达成独家研发与临床生产战略合作。

全球领先的开放式生物制药技术平台公司药眀生物与专注于肿瘤免疫和神经退行性疾病抗体新药开发的韩国生物技术公司ABL Bio Corporation今日宣布,双方针对多达八个抗体新药达成独家研发与临床生产战略合作。

根据合作协议,药明生物将为ABL Bio自有研发管线及其与天境生物的合作项目提供强有力支持。此次合作彰显了ABL Bio丰富的研发管线以及药明生物的双特异性抗体开发技术能力和强劲的产能实力。

“我们很高兴与药明生物达成独家战略合作,这将助力公司布局双特异性抗体等新一代生物创新药领域,推进公司自主研发及外部合作产品管线的开发。药明生物已成功赋能ABL Bio和天境生物,为多个临床前和临床项目提供开发和生产服务。”ABL Bio创始人兼首席执行官Sang Hoon Lee博士表示,“此次合作对ABL Bio而言意义非凡,一方面能积极拓展公司的双特异性抗体产品管线开发进程,另一方面将帮助我们跻身肿瘤免疫和神经退行性疾病领域拥有国际水平的公司之列。”


“这是我们首次与韩国合作伙伴建立独家战略合作协议,对此我感到非常荣幸。这再次证明药明生物作为开发和生产双特异抗体等高难度生物药的全球行业领导者,其国际水准的技术实力已经获得广泛认可。”药明生物首席执行官陈智胜博士表示,“药明生物打造了全球最大规模的生物药研发团队之一,在近2000名经验丰富科学家的共同努力下,我们每年可以赋能客户将60个项目推至新药临床试验申请(IND)以及3个项目推向生物制品上市申请(BLA)。凭借全球合作伙伴认可的强大生物制药技术能力及全球首屈一指的产能规模,药明生物正在变革全球生物药开发和生产进程。”

关于ABL Bio

ABL Bio是一家成立于2016年的韩国生物技术公司,专注肿瘤免疫和神经退行性疾病的抗体疗法开发。成立三年以来,公司已顺利完成近1亿美元融资,目前正在筹备韩国证券交易所(KOSDAQ)公开上市事宜。公司在研产品ABL001,即靶向VEGF和DLL4的双特异肿瘤抗体,目前已进入一期临床试验。在神经退行性疾病领域,ABL Bio正利用其双特异抗体专长,开发旨在最大化提高血脑屏障穿透性和疗效的新一代产品。现阶段,公司研发进展最快的产品ABL301,是靶向α-突触核蛋白的双特异性抗体,可以通过受体介导的转胞吞作用穿透血脑屏障,用于治疗帕金森。ABL Bio已建立起强大的研发团队,在免疫肿瘤学治疗领域积极开展Best-in-Class及First-in-Class的双特异抗体开发工作。

关于药明生物

药明生物(股票代码:2269.HK)作为一家香港上市公司,是全球领先的开放式、一体化生物制药能力和技术赋能平台。公司为全球生物制药公司和生物技术公司提供全方位的端到端研发服务,帮助任何人、任何公司发现、开发及生产生物药,实现从概念到商业化生产的全过程,加速全球生物药研发进程,降低研发成本,造福病患。截至2018年6月30日,在药明生物平台上研发的综合项目达187个,包括98个处于临床前研究阶段,78个在临床早期(I期,II期)阶段,10个在后期临床(III期)以及1个在商业化生产阶段。预计到2021年,公司在中国、爱尔兰、新加坡、美国规划的生物制药生产基地合计产能约22万升,这将有力确保公司通过健全强大的全球供应链网络为客户提供符合全球质量标准的生物药。


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1918421, encodeId=2ab419184211e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 06 18:06:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478232, encodeId=abd114e823224, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Sat Dec 01 00:06:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487235, encodeId=89eb148e2359a, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37461, encryptionId=334b3e46139, topicName=双抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbaa8296156, createdName=yeye5224615, createdTime=Sat Dec 01 00:06:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517785, encodeId=37cc151e7859b, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Sat Dec 01 00:06:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581592, encodeId=52691581592f4, content=<a href='/topic/show?id=22a08e6050d' target=_blank style='color:#2F92EE;'>#药明生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87605, encryptionId=22a08e6050d, topicName=药明生物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3e016837754, createdName=ms7421025882867189, createdTime=Sat Dec 01 00:06:00 CST 2018, time=2018-12-01, status=1, ipAttribution=)]
    2019-05-06 sunylz
  2. [GetPortalCommentsPageByObjectIdResponse(id=1918421, encodeId=2ab419184211e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 06 18:06:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478232, encodeId=abd114e823224, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Sat Dec 01 00:06:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487235, encodeId=89eb148e2359a, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37461, encryptionId=334b3e46139, topicName=双抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbaa8296156, createdName=yeye5224615, createdTime=Sat Dec 01 00:06:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517785, encodeId=37cc151e7859b, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Sat Dec 01 00:06:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581592, encodeId=52691581592f4, content=<a href='/topic/show?id=22a08e6050d' target=_blank style='color:#2F92EE;'>#药明生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87605, encryptionId=22a08e6050d, topicName=药明生物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3e016837754, createdName=ms7421025882867189, createdTime=Sat Dec 01 00:06:00 CST 2018, time=2018-12-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1918421, encodeId=2ab419184211e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 06 18:06:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478232, encodeId=abd114e823224, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Sat Dec 01 00:06:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487235, encodeId=89eb148e2359a, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37461, encryptionId=334b3e46139, topicName=双抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbaa8296156, createdName=yeye5224615, createdTime=Sat Dec 01 00:06:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517785, encodeId=37cc151e7859b, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Sat Dec 01 00:06:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581592, encodeId=52691581592f4, content=<a href='/topic/show?id=22a08e6050d' target=_blank style='color:#2F92EE;'>#药明生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87605, encryptionId=22a08e6050d, topicName=药明生物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3e016837754, createdName=ms7421025882867189, createdTime=Sat Dec 01 00:06:00 CST 2018, time=2018-12-01, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1918421, encodeId=2ab419184211e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 06 18:06:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478232, encodeId=abd114e823224, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Sat Dec 01 00:06:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487235, encodeId=89eb148e2359a, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37461, encryptionId=334b3e46139, topicName=双抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbaa8296156, createdName=yeye5224615, createdTime=Sat Dec 01 00:06:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517785, encodeId=37cc151e7859b, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Sat Dec 01 00:06:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581592, encodeId=52691581592f4, content=<a href='/topic/show?id=22a08e6050d' target=_blank style='color:#2F92EE;'>#药明生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87605, encryptionId=22a08e6050d, topicName=药明生物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3e016837754, createdName=ms7421025882867189, createdTime=Sat Dec 01 00:06:00 CST 2018, time=2018-12-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1918421, encodeId=2ab419184211e, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=12de429, createdName=sunylz, createdTime=Mon May 06 18:06:00 CST 2019, time=2019-05-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1478232, encodeId=abd114e823224, content=<a href='/topic/show?id=5e295415950' target=_blank style='color:#2F92EE;'>#战略合作#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=54159, encryptionId=5e295415950, topicName=战略合作)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ba6c7422782, createdName=ms8435843352634314, createdTime=Sat Dec 01 00:06:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1487235, encodeId=89eb148e2359a, content=<a href='/topic/show?id=334b3e46139' target=_blank style='color:#2F92EE;'>#双抗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37461, encryptionId=334b3e46139, topicName=双抗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bbaa8296156, createdName=yeye5224615, createdTime=Sat Dec 01 00:06:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1517785, encodeId=37cc151e7859b, content=<a href='/topic/show?id=44156886664' target=_blank style='color:#2F92EE;'>#生产#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=21, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68866, encryptionId=44156886664, topicName=生产)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=37a111112788, createdName=ms1343860338762272, createdTime=Sat Dec 01 00:06:00 CST 2018, time=2018-12-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1581592, encodeId=52691581592f4, content=<a href='/topic/show?id=22a08e6050d' target=_blank style='color:#2F92EE;'>#药明生物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=87605, encryptionId=22a08e6050d, topicName=药明生物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e3e016837754, createdName=ms7421025882867189, createdTime=Sat Dec 01 00:06:00 CST 2018, time=2018-12-01, status=1, ipAttribution=)]

相关资讯

药明生物正式在香港联交所挂牌交易

药明生物技术有限公司(简称“药明生物”,股票代码:2269.HK)香港主板上市仪式今日在香港联合交易所隆重举行。药明康德集团董事长兼首席执行官、药明生物董事长李革博士、药明生物执行董事兼首席执行官陈智胜博士等管理层和员工代表、政商界人士和中介机构纷纷到场,共同见证药明生物的这一重要发展里程碑。

药明生物生命科技园正式在无锡奠基

全球领先的生物制药技术平台公司药明生物(WuXi Biologics, 2269.HK)宣布在无锡开建“药明生物生命科技园”。 今天,药明生物生命科技园一期工程奠基仪式在无锡隆重举行。无锡市委常委、组织部部长周英女士等政府领导、客户代表、药明生物首席执行官陈智胜博士等多位公司高管,以及多家主流媒体记者等社会各界人士欢聚一堂,共同见证开工奠基盛典。 药明生物生命科技园

药明生物任命哈佛大学教授David R. Liu为科学顾问委员会成员

药明生物近日任命哈佛大学化学与化学生物学教授,Broad研究所副教授,霍华德休斯医学研究所(HHMI)研究员David R. Liu为科学顾问委员会(SAB)成员。

药明生物建成亚洲很大使用一次性反应器的生物制药灌流生产车间

上海和无锡2016年9月22日电 /美通社/ -- 药明康德集团企业药明生物今日宣布其在无锡的生物制药研发生产新基地正式投产。 药明生物于2015年4月宣布新建总投资1.5亿美元的全球领先的生物制药生产基地,17个月后具有国际一流水平的生物制药基地一期工程即建设完成。新基地采用一次性生产技术的2个1000升灌流生产反应器正式投入运营,标志着药明生物在无锡建成了目前已知亚洲最大使用一次